Jason Manka

Title: Jason Manka: Innovator in Neurological Treatments

Introduction

Jason Manka is a notable inventor based in Nashville, TN (US), recognized for his contributions to the field of neurological and psychiatric treatments. He holds three patents that focus on innovative compounds aimed at addressing glutamate dysfunction.

Latest Patents

Manka's latest patents include "Substituted 6-methylnicotinamides as mGluR5 positive allosteric modulators." This invention relates to substituted 6-methylnicotinamide analogs and derivatives that serve as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5). The patent outlines synthetic methods for creating these compounds, pharmaceutical compositions that include them, and methods for treating neurological and psychiatric disorders associated with glutamate dysfunction. Another significant patent is "Naphthyridinone analogs as mGluR5 positive allosteric modulators." Similar to the previous patent, this invention focuses on naphthyridinone analogs and derivatives that act as positive allosteric modulators of mGluR5, along with their synthetic methods and applications in treating related disorders.

Career Highlights

Throughout his career, Jason Manka has worked with prestigious institutions, including Vanderbilt University and F. Hoffmann-La Roche AG. His work has significantly advanced the understanding and treatment of neurological conditions.

Collaborations

Manka has collaborated with esteemed colleagues such as P. Jeffrey Conn and Craig William Lindsley, contributing to the development of innovative therapeutic solutions.

Conclusion

Jason Manka's work in the field of neurological treatments showcases his dedication to innovation and improving patient outcomes. His patents reflect a commitment to addressing critical health issues through scientific advancement.